Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Ac-2993lar
2. Itca-650
3. Ac-2993a
4. Da-3091
5. Ac-002993
6. Ly-2148568
Molecular Weight | 4187 g/mol |
---|---|
Molecular Formula | C184H282N50O60S |
XLogP3 | -21 |
Hydrogen Bond Donor Count | 58 |
Hydrogen Bond Acceptor Count | 66 |
Rotatable Bond Count | 135 |
Exact Mass | 4185.0306624 g/mol |
Monoisotopic Mass | 4184.0273075 g/mol |
Topological Polar Surface Area | 1780 Ų |
Heavy Atom Count | 295 |
Formal Charge | 0 |
Complexity | 10300 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 37 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Bydureon |
Drug Label | BYDUREON (exenatide extended-release for injectable suspension) is supplied as a sterile powder to be suspended in diluent and administered by subcutaneous injection. Exenatide is a 39-amino acid synthetic peptide amide with an empirical formula of C... |
Active Ingredient | Exenatide synthetic |
Dosage Form | For suspension, extended release |
Route | Subcutaneous |
Strength | 2mg/vial |
Market Status | Prescription |
Company | Astrazeneca Ab |
2 of 4 | |
---|---|
Drug Name | Byetta |
PubMed Health | Exenatide (Injection) |
Drug Classes | Antidiabetic |
Drug Label | BYETTA (exenatide) is a synthetic peptide that was originally identified in the lizard Heloderma suspectum. Exenatide differs in chemical structure and pharmacological action from insulin, sulfonylureas (including D-phenylalanine derivatives and megl... |
Active Ingredient | Exenatide synthetic |
Dosage Form | Injectable |
Route | subcutaneous; Subcutaneous |
Strength | 300ugm/1.2ml (250ugm/ml); 300mcg/1.2ml (250mcg/ml); 600ugm/2.4ml (250ugm/ml); 600mcg/2.4ml (250mcg/ml) |
Market Status | Prescription |
Company | Amylin; Astrazeneca Ab |
3 of 4 | |
---|---|
Drug Name | Bydureon |
Drug Label | BYDUREON (exenatide extended-release for injectable suspension) is supplied as a sterile powder to be suspended in diluent and administered by subcutaneous injection. Exenatide is a 39-amino acid synthetic peptide amide with an empirical formula of C... |
Active Ingredient | Exenatide synthetic |
Dosage Form | For suspension, extended release |
Route | Subcutaneous |
Strength | 2mg/vial |
Market Status | Prescription |
Company | Astrazeneca Ab |
4 of 4 | |
---|---|
Drug Name | Byetta |
PubMed Health | Exenatide (Injection) |
Drug Classes | Antidiabetic |
Drug Label | BYETTA (exenatide) is a synthetic peptide that was originally identified in the lizard Heloderma suspectum. Exenatide differs in chemical structure and pharmacological action from insulin, sulfonylureas (including D-phenylalanine derivatives and megl... |
Active Ingredient | Exenatide synthetic |
Dosage Form | Injectable |
Route | subcutaneous; Subcutaneous |
Strength | 300ugm/1.2ml (250ugm/ml); 300mcg/1.2ml (250mcg/ml); 600ugm/2.4ml (250ugm/ml); 600mcg/2.4ml (250mcg/ml) |
Market Status | Prescription |
Company | Amylin; Astrazeneca Ab |
DRUG PRODUCT COMPOSITIONS
Global Sales Information
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?